RxDoctor Payments Data

Adolfo Benitez, MD

Family Medicine · El Paso, TXNPI 1528268166

Payments from drug & device makers

$1,382in general payments, 2019–2025

Across 68 payments — averaging $20.32 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$315
  • Sanofi-aventis U.S. LLC$188
  • Novo Nordisk$182
  • Amgen$179
  • AstraZeneca$163
  • Lilly USA, LLC$126
  • plus $229 from 6 others

What the payments were for

  • Food & beverage$1,37299%
  • Education$101%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,382 in reported general payments places this provider in the 65th percentile of 8,760 family medicine providers in Texas.

See all family medicine providers in Texas

Medicare billing

Part B allowed, 2024
$49,853
Medicare patients
85
Services billed
749

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
TrulicityDulaglutide88$173,366
OzempicSemaglutide59$95,692
FarxigaDapagliflozin Propanediol50$62,882
JardianceEmpagliflozin31$43,774
JanuviaSitagliptin Phosphate26$37,892
EliquisApixaban20$24,839
MounjaroTirzepatide13$21,086
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog11$13,314
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog14$10,302
Lantus SolostarInsulin Glargine,hum.Rec.Anlog49$9,618
LinzessLinaclotide12$9,497
Omega-3 Acid Ethyl Esters59$7,466
Novolog FlexpenInsulin Aspart13$4,823
SymbicortBudesonide/Formoterol Fumarate18$4,380
Atorvastatin Calcium508$3,879

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Lilly USA, LLCTrulicity, Mounjaro$126$194,452101 claims
Novo NordiskOzempic$182$95,69259 claims
AstraZenecaFarxiga, Symbicort$163$67,26268 claims
Boehringer IngelheimJardiance$44$43,77431 claims
AbbVieLinzess$315$9,49712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 8,760 family medicine providers in Texas.

Other family medicine in El Paso

See the full list for Texas

Where these figures come from

Is this you, or does something look wrong? →